Sign In
Buy URGN
$26.60
+0.0600 (+0.226%)
At Close: Jun 03, 2026
Class Action Lawsuit Filed Against UroGen Pharma Ltd. (URGN) - Recover Losses - Contact Levi & Korsinsky Before July 28, 2025
06:50am, Sunday, 15'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 15, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities la
Class Action Lawsuit Filed Against UroGen Pharma Ltd. (URGN) - Recover Losses - Contact Levi & Korsinsky Before July 28, 2025
06:25pm, Saturday, 14'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 14, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities la
NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the
UroGen Pharma price target raised to $16 from $3 at Goldman Sachs
06:15pm, Friday, 13'th Jun 2025
Goldman Sachs analyst Paul Choi raised the firm's price target on UroGen Pharma to $16 from $3 and keeps a Neutral rating on the shares following yesterday's approval of Zusduri. The firm cites the st
Class Action Filed Against UroGen Pharma Ltd. (URGN) Over Securities Violations - Contact Levi & Korsinsky Today
03:30pm, Friday, 13'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities la
UroGen Pharma price target raised to $31 from $10 at Oppenheimer
03:24pm, Friday, 13'th Jun 2025
Oppenheimer analyst Leland Gershell raised the firm's price target on UroGen Pharma to $31 from $10 and keeps an Outperform rating on the shares following yesterday's approval of Zusduri. The firm say
URGN CLASS ACTION NOTICE: UroGen Pharma Ltd. Was Sued For Securities Fraud; Contact BFA Law if You Suffered Losses
03:18pm, Friday, 13'th Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ:URGN) and certai
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 28, 2025 in UroGen Pharma Ltd. Lawsuit – URGN
01:39pm, Friday, 13'th Jun 2025
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in UroGen Pharma Ltd. ("UroGen Pharma Ltd." or the "Company") (NASDAQ: URGN) of a class action securities lawsuit.
UroGen Pharma: Lessons Learned And Future Outlook
01:05pm, Friday, 13'th Jun 2025
UroGen Pharma's FDA approval for UGN-102 removes existential risk and validates a contrarian investment stance, driving a sharp stock price recovery. A key investment thesis now hinges on UGN-102's co
URGN LAWSUIT ALERT: Levi & Korsinsky Notifies UroGen Pharma Ltd. Investors - Lead Plaintiff Deadline July 28, 2025
12:45pm, Friday, 13'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities la
SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd. et al., No. 3:25-cv-06088 (D. N.J.) has been filed and seeks to represent inves
Investor Alert: Deadline Approaching to Join UroGen Pharma Ltd. (URGN) Class Action - Contact Levi & Korsinsky
11:25am, Friday, 13'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities la
Did You Lose Money on UroGen Pharma Ltd. (URGN)? Levi & Korsinsky Urges Investors to Act Before July 28, 2025
11:00am, Friday, 13'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities la
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ:URGN).
Investors Urged to Contact Levi & Korsinsky for Information Before July 28, 2025 - UroGen Pharma Ltd. (URGN)
08:15am, Friday, 13'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities la
